Compare Hasbro, Inc. (HAS) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Hasbro, Inc. trades at $96.15 (market cap $13.53B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Hasbro, Inc. is far larger — about 13.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Hasbro, Inc. pays a 2.92% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HAS | MRVI | |
|---|---|---|
Market Cap | $13.53B | $972.90M |
Volume | 1,762,034 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $9.00 |
52-Week Low | $74.13 | $2.83 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | $15.72B | $1.08B |
Dividend Yield | 2.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $95.46, up 0.77% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings beats in recent quarters (Q4 2025-Q2 2026) and positive cash flow trends, though 2025 net income was negative. Valuation metrics include a P/E of 17.07 and P/S of 2.74, while institutional interest remains high with recent purchases by HSBC and Virginia Retirement Systems.
Outlook is positive with a consensus price target of $107.60 (13% upside), supported by Magic: The Gathering growth and cost savings. Risks include high debt levels (debt-to-asset ratio of 59.09% in 2025) and sensitivity to consumer spending trends. The upcoming Q3 2026 earnings on October 20 will be a key catalyst.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
